Nibha Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nibha Jain has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Arumugam Moorthy
Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust , Birmingham, UK
2 shared publicationsAde Adebajo
Faculty of Medicine Dentistry and Health University of Sheffield Sheffield UK
1 shared publication- Adeola Ajibade
Somerset NHS Fdn Trust, Taunton, England
1 shared publication - Amita Aggarwal
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
1 shared publication - Arumugam Moorthy
University Hospitals of Leicester NHS Trust Leicester UK
1 shared publication Ash Samanta
Department of Rheumatology University Hospitals of Leicester Leicestershire UK
1 shared publication
Latest Publications
- Open Access
- 30 December 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 7 (1) , rkad029
Effectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC)
Adeola Ajibade, Haridha Pandian, Nibha Jain, Latika Gupta, Ramasharan Laxminarayan, Arumugam Moorthy, Roshan Amarasena, Natasha Cox, Hem Sapkota, Girish Kakade,
- 30 December 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 7 (1) , rkad029
Open AccessEffectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC)
Adeola Ajibade, Haridha Pandian, Nibha Jain, Latika Gupta, Ramasharan Laxminarayan, Arumugam Moorthy, Roshan Amarasena, Natasha Cox, Hem Sapkota, Girish Kakade,
- Open Access
- 1 April 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (Supplement)
P185 Does BASDAI score correlate to MRI changes in ankylosing spondylarthritis?
Background/Aims The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is routinely used subjective outcome measurement of disease activity in Ankylosing Spondylitis (AS). BASDAI > 4 is used as a criterion for commencing anti-TNF therapy. Previous studies shown BASDAI correlation with MRI has been proven to be weak. We did this study to systemically compare clinical and radiological data of patients with AS and to look for the degree of correlation between BASDAI score and MRI changes positive for spondyloarthritis in our cohort of patients. Methods A retrospective analysis of AS patients attending Leicester spondylarthritis service at University Hospitals Leicester Trust (UHL) was carried out. Clinical characteristics such as HLA-B27 status, extra-articular features, family history of AS and CRP measurement were obtained from online systems and clinic letters. Online records were reviewed to see if patients had a MRI of the sacroiliac joints along with a BASDAI score at the time of MRI. Medcalc calculator was used for statistical analysis. Results A total of 106 patients were analysed with a mean age of 45.6 +/- 11.6 years (M = 62, F = 44) with mean BASDAI of 5.0 +/- 2.5. Mean CRP was 17.01+/- 30.4 (median CRP 6.5). 61% (n = 65) were HLA-B27 positive. 70 of 106 patients had a sacroiliac MRI scan which could be reviewed to a satisfactory level to determine whether disease is present or not. Two results were statistically significant when comparing active versus no active lesions on MRI: inflammatory back pain and anti-TNF therapy ( Table 1). Conclusion BASDAI score did not statistically correlate with the severity of inflammation as objectively observed on MRI. Only inflammatory back pain and anti-TNF therapy correlated with MRI disease activity. There was no difference in clinical features including HLA-B27 between patients with active and inactive MRI. Thus, BASDAI as a criterion for biologic therapy may need re-considering. Disclosure N. Jain: None. S. Byravan: None. J. Stairs: None. W. Rennie: None. M. Arumugam: Other; Speaker and Conference Fee MSD, Novartis, Abbvie.
- 1 April 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (Supplement)
Open AccessP185 Does BASDAI score correlate to MRI changes in ankylosing spondylarthritis?
Background/Aims The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is routinely used subjective outcome measurement of disease activity in Ankylosing Spondylitis (AS). BASDAI > 4 is used as a criterion for commencing anti-TNF therapy. Previous studies shown BASDAI correlation with MRI has been proven to be weak. We did this study to systemically compare clinical and radiological data of patients with AS and to look for the degree of correlation between BASDAI score and MRI changes positive for spondyloarthritis in our cohort of patients. Methods A retrospective analysis of AS patients attending Leicester spondylarthritis service at University Hospitals Leicester Trust (UHL) was carried out. Clinical characteristics such as HLA-B27 status, extra-articular features, family history of AS and CRP measurement were obtained from online systems and clinic letters. Online records were reviewed to see if patients had a MRI of the sacroiliac joints along with a BASDAI score at the time of MRI. Medcalc calculator was used for statistical analysis. Results A total of 106 patients were analysed with a mean age of 45.6 +/- 11.6 years (M = 62, F = 44) with mean BASDAI of 5.0 +/- 2.5. Mean CRP was 17.01+/- 30.4 (median CRP 6.5). 61% (n = 65) were HLA-B27 positive. 70 of 106 patients had a sacroiliac MRI scan which could be reviewed to a satisfactory level to determine whether disease is present or not. Two results were statistically significant when comparing active versus no active lesions on MRI: inflammatory back pain and anti-TNF therapy ( Table 1). Conclusion BASDAI score did not statistically correlate with the severity of inflammation as objectively observed on MRI. Only inflammatory back pain and anti-TNF therapy correlated with MRI disease activity. There was no difference in clinical features including HLA-B27 between patients with active and inactive MRI. Thus, BASDAI as a criterion for biologic therapy may need re-considering. Disclosure N. Jain: None. S. Byravan: None. J. Stairs: None. W. Rennie: None. M. Arumugam: Other; Speaker and Conference Fee MSD, Novartis, Abbvie.
- Open Access
- 26 June 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 23 (7) , 849-852
COVID‐19 and ethnicity: Spotlight on the global rheumatology issues in developing and developed countries
- 26 June 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 23 (7) , 849-852
Open AccessCOVID‐19 and ethnicity: Spotlight on the global rheumatology issues in developing and developed countries